{
}
UBS has maintained a "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton highlighted current prescription trends in the U.S. for the GLP-1 active ingredient, known for its appetite-suppressing effects.
UBS has rated Novo Nordisk as a 'Buy', but the information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investing in securities carries risks, including the potential total loss of capital, and does not replace tailored expert investment advice. No liability for the accuracy or completeness of the information is assumed.
Novo Nordisk's shares have dropped over 20% this year, primarily due to disappointing results for its weight loss drug CagriSema and concerns about Wegovy's market performance against Eli Lilly's Zepbound. Despite this, UBS maintains a "buy" rating with a target price of 750 DKK, suggesting a potential 56% upside. Wall Street remains divided, with half of analysts recommending a buy and the other half advising to hold, but no sell ratings are present.
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns, influenced by current trends in weight loss drugs, particularly GLP-1. Analyst Jo Walton noted growth for Eli Lilly's Zepbound, while other competitors are seeing declines.
UBS has rated Novo Nordisk as a 'Buy', but the information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investing in securities carries risks, including the potential total loss of capital. No liability for the accuracy or completeness of the information is assumed.
Novo Nordisk A/S focuses on the design, manufacture, and marketing of pharmaceutical products, with 93.6% of sales from diabetes and obesity treatments and 6.4% from rare diseases. Geographically, 57.6% of sales are in the United States, followed by Europe-Middle East-Africa at 20.8% and China at 6.4%.
UBS has rated Novo Nordisk as a 'Buy', but the information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investing in securities carries risks, including the potential total loss of capital, and expert investment advice is recommended. No liability for the accuracy or completeness of the information is assumed, and the content reflects the views of individual authors rather than wallstreetONLINE.
Novo Nordisk A/S focuses on the design, manufacture, and marketing of pharmaceutical products, with 93.6% of sales from diabetes and obesity treatments and 6.4% from rare disease therapies. Geographically, 57.6% of sales come from the United States, followed by Europe-Middle East-Africa at 20.8%, and other regions contributing the remainder.
UBS has maintained a Neutral rating on Eli Lilly (NYSE: LLY) with a price target of $1,100, noting a recent uptick in prescriptions for Zepbound despite previous product performance setbacks. The company has seen a 32% revenue growth over the past year, with expectations for Zepbound adjusted upward by 2%. Looking ahead, the anticipated release of orfo diabetes data in Q2 2025 could significantly boost investor interest, with a 70% probability of success for the ACHIEVE-1 study.
UBS has maintained a "Neutral" rating on Eli Lilly (NYSE: LLY) with a price target of $1,100, noting the company's strong revenue growth despite recent product performance setbacks. The upcoming release of Orfo diabetes data in Q2 2025 is highly anticipated, with a 70% probability of success for the ACHIEVE-1 trial, which could enhance investor interest. Eli Lilly's recent launch of Mounjaro in India positions it competitively in a market facing rising obesity and diabetes rates.
Novo Nordisk A/S
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating for novo nordisk with target price of 750 crowns
22:34 31.03.2025
ubs rates novo nordisk as buy amid investment considerations and risks
20:17 31.03.2025
ubs predicts over 50 percent recovery for novo nordisk shares
19:30 28.03.2025
ubs maintains buy rating for novo nordisk with target price of 750 crowns
16:06 28.03.2025
ubs rates novo nordisk as a buy with investment risks highlighted
16:06 28.03.2025
Novo Nordisk's strong sales driven by diabetes and obesity treatments
15:52 28.03.2025
ubs rates novo nordisk as a buy with investment risks highlighted
08:48 28.03.2025
novo nordisk reports strong sales in diabetes and obesity treatments
08:35 28.03.2025
ubs maintains neutral rating on eli lilly with 1100 price target
15:33 24.03.2025
ubs maintains neutral rating on eli lilly with price target of 1100
15:26 24.03.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
Central Bank Actions
GDP Growth & Recession Forecasts
CEO Changes
Global Trade Developments
Industry Mergers & Acquisitions
Financial Scams and Security
Market Analysis and Predictions
Inflation and Monetary Impact
Government Policies
Government Economic Policies
Supply Chain Management
Domestic Politics
Workplace Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Bank of America Corporation
Barclays PLC
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Credit Suisse Strategic Income I
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
Swiss Re AG
Beazley plc
UBS AG
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Canadian Dollar
Australian Dollar
United Arab Emirates Dirham
Saudi Riyal
South Korean Won
Danish Krone
Offshore Chinese Yuan
Hong Kong Dollar
Mexican Peso
Indonesian Rupiah
Malaysian Ringgit
Vietnamese Đồng
People: